Provention Bio, a biopharmaceutical company based in Red Bank, recently announced the closing of a $35 million equity investment from Bridgewater-based Sanofi US. The deal is part of a previously ...

Following Sanofi‘s $35 million equity investment last month, the global health care company will acquire Red Bank-based Provention Bio Inc. for $25 per share, representing an equity value of ...

-If Approved Teplizumab will be the First Disease-Modifying Therapy for Type 1 Diabetes - Certain statements in this press release are forward-looking, including but not limited to, statements ...

Provention Bio Inc (NASDAQ:PRVB) shares are rocketing higher Monday after Sanofi (NASDAQ:SNY) announced plans to acquire the biopharmaceutical company. What Happened: Sanofi and Provention Bio entered ...

Tourlite Capital Management, an investment management company, released its fourth-quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, Tourlite Fund Founder ...

(Reuters) -France's Sanofi SA on Monday agreed to acquire Provention Bio Inc for $2.9 billion to bolster its work on a U.S.-approved type 1 diabetes therapy and strengthen its drug pipeline following ...

Sanofi understandably likes the idea of adding Provention's Tzield product to its lineup. The drug won U.S. regulatory approval in 2022 to delay the onset of stage 3 type 1 diabetes (T1D) in adults, ...

The U.S. antitrust watchdog is taking more time to review the proposed combination of Sanofi and Provention Bio, two diabetes drug developers. Meanwhile, all eyes in biopharma are on the merger ...

Sanofi SA said Monday that it has entered into an agreement to acquire U.S.-based biopharmaceutical company Provention Bio, Inc. for around $2.9 billion, or $25 a share. The French pharma major said ...

Provention Bio (PRVB) is a great speculative biotech play to look into. The reason why I state that is because it received FDA approval of TZIELD for stage 2 Type 1 Diabetes (T1D) patients. The goal ...

Sanofi plans to acquire Provention Bio for around $2.9 billion. The deal will add Provention's type 1 diabetes drug Tzield to Sanofi's lineup. Sanofi and Provention Bio expect the transaction to close ...